




The relative strengths and weaknesses of Statera Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Statera Biopharma Inc is the variable Expenses, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 270%, being 20% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	4,476
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	912
Liabilities, Non-Current	8.5
Other Assets	30
Other Compr. Net Income	0.56
Other Expenses	0
Other Liabilities	0
Other Net Income	2,231
Other Revenues	0
Property and Equipment	28
Research and Development	3,619
Selling, General and Administrative Expense	2,319

Output Variable	Value in 1000 USD
Assets	4,534
Liabilities	920
Expenses	5,938
Revenues	0
Stockholders Equity	3,614
Net Income	-3,707
Comprehensive Net Income	-3,707
BaseVar	6,812
ECR before Limited Liability	153%
Economic Capital Ratio	270%